Introduction
============

Niemann-Pick Diseases (NPD) is a disorder that affects multiple organ systems. It has an extensive range of presenting symptoms which differ in severity. NPD is classified into four types: A, B, C1, and C2. These types are classified based on the genetic cause, clinical signs and presenting symptoms ([@B1]). NPD type A and B are also known as a SMPD1-associated disease which constitutes different clinical phenotypes of a primary sphingomyelin storage disorder resulting from acid sphingomyelinase deficiency due to SMPD1 gene mutations ([@B2]-[@B4]). The classical phenotype of NPD is often described as hepatosplenomegaly, with progressive ataxia, dystonia, and dementia. NPD type A is the most common type present in infants and is characterized by jaundice, hepatomegaly, failure to thrive, progressive deterioration of the nervous system and profound brain damage most often leading to death before 18 months of age ([@B5]). Type A is most common amongst those from Ashkenazi (eastern and central European) Jewish descent ([@B6]).

In NPD type B patients, hepatosplenomegaly is often present which may be severe in the presence or absence of signs of liver failure. Serum low-density lipoprotein (LDL)-cholesterols and triglycerides are often elevated in NPD, although high-density lipoprotein (HDL)-cholesterol is found to be at low levels. Another clinical sign present in some type B cases is a distinct cherry-red spot in the macula ([@B7]). Type B patients have no overt signs of central nervous system involvement but frequently have compromised pulmonary function ([@B6]). NPD type C can present in infancy, childhood, or adulthood. Neonates may present with severe ascites due to severe liver disease or respiratory failure as well as renal failure ([@B8], [@B9]). Newborns presenting without liver or pulmonary disease, often present with hypotonia and developmental delay ([@B1]).

NPD type C most commonly develops in late childhood with most patients not surviving to the second decade of life ([@B2]-[@B4]). Other phenotypes include fatal neonatal liver disease, delayed motor development and early infantile onset with hypotonia. Adult variations in the phenotype include onset of psychosis and dementia, juvenile dystonic lipidosis, DAF (downgaze paresis, ataxia, foam cells) syndrome, adult dystonic lipidosis, dystonia, and organomegaly, all of now recognized as presentations of NPD ([@B9]-[@B11]).

In this case series, we describe 19 cases to illustrate the clinical manifestations of NPD and further discuss the variations in the genetics findings and biochemistry.

Case Presentation
=================

In this study, we present 19 patients with ranging types of NPD including Type A, B, C, and C1. All cases who presented, were admitted to their local hospital due to onset of health complications. Each patient underwent a complete clinical assessment ([Table 1](#T1){ref-type="table"}). Each case also underwent the appropriate biochemical investigations, which revealed enzymatic defects. Post-genetic counseling and molecular investigations such as Sanger sequencing were performed to confirm the clinical diagnosis of NPD and determine the type of NPD present in all patients.

Written informed consent was obtained from all subjects and the study protocol has been approved by the Regional Ethics Committee in the field of human research, in their local universities.

Two cases had NPD type A, both of whom died in infancy. Six patients had type B NPD of which four died by 4.5 years of age and two are currently alive and under three years of age. Eleven patients had/ have NPD type C/ C1. Five of the patients were born to parents not-related and 14 to consanguineous parents ([Table 1](#T1){ref-type="table"}). Fourteen patients had hepatosplenomegaly and elevated liver enzymes, and 15 patients had developmental and psychomotor regression. Two cases had an auditory impairment and four with a visual impairment. In 10 cases we identified novel mutations predicted likely pathogenic.

Discussion
==========

In this case series, we have presented 19 different patients from different families and nationality with NPD type A, B, C, and C1. Data were consolidated for the clinical manifestations and biochemical findings as well as genetic investigations performed. This case series provides clinical data on 19 patients with NPD with 10 novel previously undescribed mutations along with formerly reported mutations. Clinical symptomatology and disease progression in NPD are markedly affected by the age of disease onset of neurological manifestations also suggested elsewhere ([@B11]).

###### 

Each patients' clinical findings including and genetic information with mutation identified

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Case Number**                                   **1**                    **2**                   **3**                 **4**                                                        **5**                 **6**                   **7**                   **8**                       **9**                 **10**              **11**             **12**              **13**          **14**                  **15**                   **16**                   **17**                 **18**                **19**
  ------------------------------------------------- ------------------------ ----------------------- --------------------- ------------------------------------------------------------ --------------------- ----------------------- ----------------------- --------------------------- --------------------- ------------------- ------------------ ------------------- --------------- ----------------------- ------------------------ ------------------------ ---------------------- --------------------- ----------------------
  **Current Age**                                   Died at \~6 months old   Died at 2.5 years old   Died at 3 years old   Died at 4.5 years old                                        Died at 3 years old   Died at 1.5 years old   Alive - 1.5 years old   Alive - 2.4 years old       Died at 2 years old   Alive - 3.5months   Alive - 6 months   Alive - 4.9 years   Died at birst   Died at 2.4 years old   Alive - 28.5 years old   Alive - 29.5 years old   Alive - 46 years old   7 months              Alive - 25 years old

  **Gender**                                        Male                     Male                    Female                Male                                                         Female                Male                    Male                    Female                      Female                Male                Female             Male                Female          Female                  Male                     Female                   Male                   Female                Female

  **Ethnicity**                                     Arab Iranian             Arab Iranian            Arab Iranian          Bakhtiari                                                    Lor (Baghmalek)       Arab Iranian            Fars                    Fars                        Bakhtiari             Fars                Fars               Fars                Fars            Fars                    Fars                     Fars                     Fars                   Fars                  Turk (Azari)

   \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  **Medical & Family History**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Consanguinity of parents\'**                    Second cousin            First cousin            First cousin          First cousin                                                 First cousin          First cousin            Not related             First cousin                First cousin          Not related         First cousin       First cousin        First cousin    First cousin            Not related              Not related              Not related            First cousins         Distantly related

  **Other family members with NPD, if yes, Type**   N                        N                       N                     N                                                            N                     N                       N                       N                           N                     N                   N                  N                   Y - Type C      Y - Type C              Y - Type C               Y - Type C               Y - Type C             N                     N

  **Age of Diagnosis**                              6 months                 5 months                6 months              6 months                                                     6 months              7 months                Unknown                 Unknown                     6 months              3 months            5 months           4.5 years           At birth        6 months                27 years                 28 years                 44 years               6 months              25 years

  **Neonatal icterus (Y / N)**                      N                        N                       Y                     Y                                                            N                     Y                       Y                       Y                           N                     Y                   Y                  Y                   N               N                       N                        N                        N                      N                     N

  **Failure to thrive (Y / N)**                     N                        N                       N                     N                                                            N                     N                       Y                       N                           Y                     Y                   Y                  Y                   Y               Y                       N                        N                        N                      N                     N

  **Splenomegaly (Y / N)**                          Y                        Y                       Y                     Y                                                            Y                     Y                       Y                       Y                           Y                     Y                   Y                  Y                   Y               Y                       N                        N                        N                      Y                     N

  **Hepatomegaly (Y / N)**                          Y                        Y                       Y                     Y                                                            Y                     Y                       Y                       Y                           Y                     Y                   Y                  Y                   Y               Y                       N                        N                        N                      Y                     N

  **Any intellectual disability (Y / N)**           Y                        Y                       N                     Y                                                            N                     N                       Y                       Y                           N                     Y                   Y                  Y                   NA              Y                       Y                        Y                        Y                      N                     Y

  **Developmental regression (Y / N)**              Y                        Y                       Y                     Y                                                            Y                     Y                       Y                       Y                           Y                     Y                   Y                  Y                   NA              Y                       N                        N                        Y                      Y                     Y

  **Gaze paresis (Y / N)**                          N                        N                       N                     N                                                            N                     N                       N                       N                           N                     N                   N                  N                   NA              Y                       Y                        Y                        Y                      N                     Y

  **Epilepsy (Y / N)**                              N                        Y                       N                     N                                                            N                     N                       N                       N                           N                     N                   N                  N                   NA              N                       N                        N                        Y                      N                     Y

  **Mental illness (Y / N)**                        Y                        Y                       Y                     N                                                            N                     N                       N                       N                           N                     N                   N                  N                   NA              Y                       Y                        Y                        Y                      Y                     Y

  **Cardiac abnormalities (Y / N)**                 N                        N                       N                     N                                                            N                     N                       N                       N                           N                     RVH                 N                  N                   NA              N                       N                        N                        N                      N                     N

  **Hearing impairment (Y / N)**                    N                        N                       N                     N                                                            N                     N                       N                       N                           N                     N                   N                  N                   NA              Y                       N                        N                        N                      N                     N

  **Visual impairment, if yes, specify**            N                        Cherry-red spot         N                     N                                                            N                     N                       Cherry-red spot         N                           Cherry-red spot       N                   N                  N                   NA              Y                       N                        N                        N                      N                     N

   \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  **Genetics**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Gene**                                          SMPD1                    SMPD1                   SMPD1                 SMPD1                                                        SMPD1                 SMPD1                   SMPD1                   SMPD1                       NPC1                  NPC1                NPC1               NPC1                NPC1            NPC1                    NPC1                     NPC1                     NPC1                   NPC1                  NPC1

  **Mutation**                                      c.740delG                c.740delG               c.108delG             c.98_144delTGGGCCTGGTGCTGGCGCTGGCGCTGGCGCTGGCGCTGGCGCTGGCT   c.1110delT            c.573delT               c.1390G\>T              c.1524G\>A                  c.2920_2923delCCTG    c.2740 T\>A         c.1415T\>C         c.1415T\>C          c.3478-6T\>A    c.3478-6T\>A            c.2476_2484del           c.2476_2484del           c.2476_2484del         c.960_961dup          c.409A\>G

  **Amino acid Substitution**                       G247Afs\*10              G247Afs\*10             L37Wfs\*40            M33Tfs\*3                                                    L371Ffs\*14           S192Afs\*65             p.Glu464Ter             P.Gly508Gly -no AA change   C976Ffs\*6            p.Cys 914 Ser       p.Leu472Pro        p.Leu472Pro         Unknown         Unknown                 p.Ser826_Leu             p.Ser826_Leu             p.Ser826_Leu           p.(Ala321Glyfs\*16)   Thr137Ala

  **Novel mutation (Y / N)**                        N                        N                       Y                     Y                                                            Y                     N                       Y                       N                           Y                     Y                   Y                  Y                   N               N                       N                        N                        N                      Y                     Y

  **Pathogenic (Y / N)**                            Y                        Y                       Likely                Likely                                                       Likely                Y                       Likely                  Y                           Likely                Likely              Likely             Likely              Y               Y                       N                        Y                        Y                      Y                     Y
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Overall, the main complication present in most cases was liver disease, affecting 14 patients out of 19. Liver disease is known to be a cause of significant morbidity and mortality in NPD. The diagnosis of NPD type C should be considered in patients with unexplained neonatal hepatitis especially in the presence of splenomegaly ([@B12]). NPD should also be high on the differential diagnosis in the presence of systemic symptoms such as neonatal jaundice and isolated splenomegaly, neurological symptoms such as dystonia, dementia, cataplexy and supra nuclear gaze palsy which may occur in patients ([@B13]). In this case series, we have presented 10 patients who were female and 9 males. All cases with type A or B NPD had mutations in *SMPD1* and all those with NPD type C on *NPC1*. Identification of mutations in *NPC1* is challenging due to the relatively large nature of the gene and majority of the mutations being private ([@B12]).

There are 3 types of NPD that the primary biological defect is different ([@B13]). NPD types A and B are autosomal recessive lysosomal storage diseases caused by the deficient activity of acid sphingomyelinase due to mutations in the *SMPD1*. Genetic variants which are considered as disease causing are distributed in *SMPD1* gene. Most of these variants are missense or frameshift mutations ([@B14]). In this case series, eight of the cases had mutations in *SMPD1* predicted to be pathogenic or likely pathogenic. Studies have shown that the *SMPD1* is preferentially expressed from the maternal chromosome ([@B15]). In Iran, the first molecular diagnosis of NPD type A was reported. It had detected a novel deletion in SMPD1 gene ([@B16]). A novel mutation in exon 9 of NPC1 gene was reported from Khorasan Province, Iran ([@B17]).

Consanguineous marriage is common upon our region ([@B18]) and consanguinity was observed between the parents of 14 cases; however, both developmental and psychomotor regression were observed in all but two cases presented. Mongolian spots and cherry-red spot were present in three cases. Case 13 and 14 were deceased prior to the final genetic investigations were performed.

**In conclusion,**these findings in NPD have clinical implications for genetic counseling. Our study provides a large number of patients with varying presentations and novel mutations. In suspected NPD, clinicians should confirm the carrier status of both parents and evaluate other first-degree relatives to provide families with accurate genetic counseling.
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